Percentage of disabled RRMS subjects (EDSS score ≥3.5) with improvement in T25FW from best baseline walk over 30 months following randomization to natalizumab or placebo in the AFFIRM study: sensitivity analyses by consistency of improvement.
收藏数据链接：
官方服务：
资源简介：
P values assessing the difference between treatment groups based on two-sided Fisher exact test.RRMS, relapsing-remitting multiple sclerosis; EDSS, Expanded Disability Status Scale; T25FW, timed 25-foot walk.
创建时间：
2015-12-02
